Canakinumab：连个过场都不走

只剩下救命的稻草Potentially clinically meaningful improvements in both PFS and OS were observed among pre-specified subgroups of patients with inflammatory biomarkers

晚期不行，有寄希望于早期：Patients in the CANOPY-A study more closely reflect the earlier CANTOS study population than those in the CANOPY-1 trial

今年ESMO公布了CANOPY-2即canakinumab+多西他赛 vs 多西他赛 in  2L NSCLC的结果：

Canakinumab可以通过结合IL-1β来阻断相关炎症信号

FDA批了好几个适应症

在针对炎症性动脉粥样硬化的CANTOS研究中，发现Canakinumab不仅可以心血管风险，还能降低癌症的总体死亡率（A）、肺癌的发生率（B）和死亡率（C），且风险降低和剂量呈现相关性，300mg可以试肺癌发生率和死亡率分别降低67%和77%：

  • 患者基线没有肿瘤，但24%和半数的患者为吸烟者或曾吸烟者，且有较高水平炎症(hsCRP)，所以预设了肺癌的探索性分析

所以随后启动了4项NSCLC相关的研究，涉及各个分期，但是现在已经挂了2个：

  • CANOPY-A (NCT03447769) is a double-blind, placebo-controlled Phase III trial studying canakinumab in the adjuvant setting following surgical resection and cisplatin-based chemotherapy, if required2. The adjuvant study is designed to determine if treatment with canakinumab can prevent cancer relapse.

  • CANOPY-N (NCT03968419) is a Phase II neoadjuvant trial evaluating canakinumab either as monotherapy or in combination with pembrolizumab among patients with resectable NSCLC prior to their planned surgery.

  • CANOPY-1 (NCT03631199) was a double-blind, placebo-controlled Phase III trial evaluating canakinumab as a first-line treatment for locally advanced or metastatic NSCLC in combination with pembrolizumab and platinum-based doublet chemotherapy4. As reported today, the trial did not met its primary endpoints of overall survival (OS) and progression-free survival (PFS).

  • CANOPY-2 (NCT03626545) was a double-blind, placebo-controlled Phase III trial investigating the role of canakinumab in combination with the chemotherapy agent docetaxel in second- or third-line therapy versus docetaxel alone in NSCLC12. In March 2021, Novartis announced that the trial did not meet its primary endpoint, and data were presented at the European Society of Medical Oncology (ESMO) 2021 Congress.

赞 (0)

相关推荐